Summary of my readings of PYC reports.
Stephanie Unwin CEO( from August)
PYC is working on its own patented library of millions of Phylomers to find the best ones for specific purposes such as drug delivery, esp Cancer drugs. ( Called FPP’s). Currently it looks as if they have the best drug carrier in the world ( way better than TAT)and it also allows the cargo( eg a cancer drug) to escape being consumed by then cell’s defences ( known as the endosomal trap). Each drug needs a different carrier ( read multiple licences over time) They are simultaneously working on a handful of candidates to inhibit MYC (which is like the fuel that keeps cancer going). Stop supplying fuel and the cancer stops growing and the body can easily defeat it then.. So they have many carriers, and 5 drugs( but will choose the best 1) , and are working on proving these two things both separately and together act effectively. They have pretty much proven it in mice, and will now work on rats for the next 6 months, as this will mean more when compared to us humans.. If this so produced data is as good as it seems to be so far, then a major pharma will have no trouble in signing a significant deal which could be worth many many millions to the company and make the company worth multiples of today’s value. The company chair believes they will land a deal this year, maybe 2 by this time next year.. The quantum is the question. If in fact it is the holy grail to cure many cancers the sky is the limit, and each combination will end up being a separate deal, adding further revenue to the company and the potential of further work to progress more areas.. The company has used the Trojan horse ( FPP) and SAS soldier( iMYC candidate) analogy and it makes sense if you realise there are many horses and many more soldiers. Remember, the Chief scientific Officer ( Dr Robert Hayes ) has taken the position as he believes the science is the best in the world. They have good toxicity and half life work under their belt, and seem not worried by any aspect of this area of progress.
The cancers it seems to be working on are blood, colon, possibly neuroblastoma, breast… approx. 60% of cancers depend on MYC so it could be all of these., but work is also being done in other areas like muscle atrophy conditions, but this is not as advanced.
They are about to patent most of this FPP related material this month ( July 2017 ) , then scientific papers will be submitted to journals which will awaken the scientific and thereby business community world wide to this company and its potential. iMYC candidates( cancer drugs) will be patented around Q1 2018( the first one at least) . The share price may will be driven by the anticipation of success as usual so it will be interesting to watch the interest in the minnow PYC when peer reviewed publications become available ( ? later this year) . Shares are tightly held and not that easy to get. Approx 27% by one family and 23% by four other investors so a takeover is controllable by these 2 groups.
They are also doing similar work with Genetech and novel antibiotics and could well land a further milestone payment this year of several million US dollars. Work is progressing well so this is probably more likely than not. This will be significant in the sense that it will add more revenue to the coffers, but as antibiotic resistance gets more deadly/ press then governments might start being interested in this technology as well.
Current price 4.7c = mcap $94 million. Do the maths……… a Disallowed to a billion dollar mcap and that would be just the start if the company gets all this to work. Cash runway set (to end 2018) for all this to play out so no more cheap issues. Buying on market is the only way in.
Disclaimer I hold a ute full.( others have truckloads)
Expand
(20min delay)